Asunto(s)
Adenomioepitelioma , Neoplasias de la Mama , Humanos , Adenomioepitelioma/patología , Adenomioepitelioma/cirugía , Adenomioepitelioma/diagnóstico por imagen , Femenino , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , Neoplasias de la Mama/diagnóstico , Persona de Mediana EdadAsunto(s)
Carcinoma Lobular , Neoplasias de la Mama Triple Negativas , Humanos , Femenino , Carcinoma Lobular/patología , Neoplasias de la Mama Triple Negativas/patología , Persona de Mediana Edad , Neoplasias de la Mama/patología , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/cirugía , Invasividad NeoplásicaAsunto(s)
Fibroadenoma , Hemorragia , Humanos , Fibroadenoma/patología , Fibroadenoma/cirugía , Fibroadenoma/complicaciones , Fibroadenoma/diagnóstico , Femenino , Hemorragia/etiología , Enfermedad Aguda , Neoplasias de la Mama/complicaciones , Neoplasias de la Mama/patología , Neoplasias de la Mama/cirugía , AdolescenteRESUMEN
Glycosylphosphatidylinositol-specific phospholipase D (GPLD1) is a specific enzyme for glycosylphosphatidylinositol (GPI) anchors, thereby exerting its biological functions by cleaving membrane-associated GPI molecules. GPLD1 is abundant in serum, with a concentration of approximately 5-10 µg/mL. Previous studies have demonstrated that GPLD1 plays a crucial role in the pathogenesis of numerous chronic diseases including disorders of lipid and glucose metabolism, cancer, and neurological disorders. In the present study, we reviewed the structure, functions, and localization of GPLD1 in chronic diseases, as well as exercise-mediated regulation of GPLD1, thus providing a theoretical support to develop GPLD1 as a new therapeutic target for chronic diseases.
Asunto(s)
Enfermedad Crónica , Fosfolipasa D , Humanos , Fosfolipasa D/metabolismo , Neoplasias/metabolismo , Enfermedades Metabólicas/metabolismo , Enfermedades del Sistema Nervioso/metabolismoRESUMEN
BACKGROUND: There is a big difference in the expression of miRNAs of plasma exosomes of patients with HBV infection. This study aims to analyze four molecular markers of peripheral blood plasma exosomes to evaluate their potential diagnostic values in HBV infection. METHODS: A total of 55 cases of patients with chronic hepatitis B were in Experimental Group 1; 49 cases of hepatitis B carriers were in Experimental Group 2, and 46 cases were in the healthy control group. The total RNA of the plasma exosome was used to analyze the specificity and sensitivity and draw ROC curves. RESULTS: There was a significant difference in the expression of miRNA-1246, miRNA-150-5p, miRNA-5787, and miRNA-8069 down-regulated by plasma exosomes in Experimental Group 1 and Group 2 and Control Group, with a p value of less than 0.05. CONCLUSIONS: The molecular markers down-regulated were miRNA-1246, miRNA-150-5p, miRNA-5787, and miRNA-8069. The four miRNAs were initially identified as new markers of miRNAs of peripheral blood plasma exosomes after HBV infection. It is better to use multiple markers for combined diagnosis.
